Ventured is a podcast that delves into the exciting and fast-paced world of venture capital, health care innovation, entrepreneurship, and more. Through insightful interviews with industry experts, successful entrepreneurs, and venture capitalists, the show offers a unique perspective on the latest trends, strategies, and innovations that are driving health care forward. Whether you’re an aspiring entrepreneur, an experienced investor, or simply interested in the latest developments in health care and technology, Ventured provides an engaging and informative exploration of the people, ideas, and innovations that are shaping our future.
In this episode, your host Rob Moss sits down with James Bauersmith, JD, MS, a highly accomplished health care executive with extensive experience across multiple segments of the industry.
Joining UPMC Enterprises as the Vice President of Translational Sciences in 2021, James brings a wealth of knowledge and expertise to the table. Before his role at UPMC, he served as the Chief Strategic Officer and General Counsel of ByHeart, Inc., a leading infant formula company. At ByHeart, James played a pivotal role in shaping the company’s FDA strategy, overseeing legal affairs, and spearheading the acquisition and establishment of their state-of-the-art manufacturing facility.
With a robust background in the pharmaceutical sector, James spent over 15 years in various leadership positions at companies like Fresenius Kabi and Amneal Pharmaceuticals. Notably, he served as the Senior Vice President at Fresenius Kabi, responsible for overseeing the company’s portfolio and marketing strategy unit.
Listen as Rob and James delve into the intriguing realm of how payers handle novel therapeutics in the pharmaceutical industry. They explore the complex dynamics and challenges involved in introducing innovative therapeutic treatments, providing valuable insights from the manufacturer, payer, and consumer perspectives. Join us as we navigate the ever-evolving landscape of health care and uncover the critical role payers often play in shaping the future of novel therapeutics.
